Medtech icon Dr. Tom Fogarty tells MassDevice.com about his unconventional path from upstart tinkerer in the suburbs of Cincinnati to healthcare celebrity in the heart of Silicon Valley, in Part 1 of a 3-part series.
SinuSys CEO Thomas Schreck and CMO Dr. Jerome Hester tell MassDevice.com how they hope to replace sinus surgery with a simple, in-office procedure and how a doctor and his patient formed a company together.
Officials at Stryker discuss the company's Q1 2014 earnings. The company reported profits of $70 million, or 18¢ per share, on sales of $2.31 billion for the 3 months ended March 31, for profit loss of 77% on sales growth of 5.3%.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Aesthetics company Allergan adopts a "poison pill" shareholder plan in order to fend off an unsolicited $47 billion offer from Valeant Pharmaceuticals and activist investor Pershing Square Capital Management.
Aesthetics products maker Allergan (NYSE:AGN) last night adopted a "poison pill" strategy designed to insulate the company from a surprise $47 billion hostile takeover.
U.S. healthcare regulators will meet tomorrow to consider banning the use of electrical shocking devices used in behavior modification.
The FDA's neurological devices panel will meet tomorrow to decide the fate of aversive electrical stimulation, devices that generate electrical shocks used by care providers in order to deter unwanted behavior.
We're in the middle of a revolution in prosthetics, with true bionic integration just over the horizon. But a hidebound Medicare could prevent thousands of amputees from receiving the cutting-edge - and costly - devices.